Fusion Pharmaceuticals increases IPO offering to US$230-million amid strong investor demand

ad+1

The IPO values the cancer drug developer at US$583-million to US$700-million


from Report on Business - The Globe and Mail
Read The Rest:theglobeandmail...

0 comments: